Marinus Pharmaceuticals, a clinical-stage biotech developing an add-on therapy for adults with epilepsy, filed on Monday with the SEC to raise up to $63 million in an initial public offering. The New Haven, CT-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol MRNS. Marinus initially filed confidentially on April 4, 2014. Stifel and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
